SASanjith Aaron

Sanjith Aaron

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sanjith Aaron has a total of 341 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    What percentage of severely impaired stroke survivors retain residual voluntary EMG?

    by Monisha Yuvaraj, Steffi Graff, Prabhakar Appaswamy Thirumal, Sanjith Aaron, Ander Ramos-Murguialday, Nebojsa Malesevic, Christian Antfolk, Etienne Burdet, Skm Varadhan, Sivakumar Balasubramanian

    Back-ground: Beneficial rehabilitation interventions for severely impaired stroke patients are limited. Owing to practical constraints in the routine clinical use of electroencephalogram (EEG)-based brain-computer interfaces, this study investigates the feasibility of using a more practical electromyography (EMG) to detect movement intention in severe stroke subjects without visible movement. Currently, no large-scale studies provide strong evidence in favour of EMG-based human-machine interaction for closed-loop control of robotic assistance for severe stroke. Objective: To screen severely impaired stroke subjects without active wrist extension for the presence of residual EMG activity. Methods: High-density surface EMG was recorded from the wrist extensor muscles of 100 severely impaired stroke survivors while they repeatedly attempted wrist extension. EMG activity during “Rest” and “Move” states was compared, and subjects showing statistically greater muscle activity during Move than Rest were classified as having residual EMG. A modified Hodges detector combined with the probability difference-sum ratio (PDSR) was used for classification, with a threshold of 0.73 identifying subjects with residual EMG. Results: Of the 100 subjects without active wrist extension (Muscle power: MRC < 2), 64 exhibited residual EMG activity, supporting the feasibility of EMG for movement intention detection. Among these, 35 demonstrated consistent muscle activity (Detection probability > 0.2); representing suitable candidates for EMG-driven robot-assisted therapy. Conclusions: A substantial proportion of severely impaired stroke subjects without active movement could benefit from a simpler EMG-based interface for robot-assisted therapy. Distinct neural mechanisms (intact voluntary drive or abnormal co-activation) may contribute to the residual muscle activity, which should be considered while designing control strategies.

  • Open Access

    Long-term functional outcomes and caregiver burden in survivors after decompressive hemicraniectomy for malignant hemispheric infarction: a real-world experience from South India

    by Harikrishna SaiPramodh Veliveli, Angel T Miraclin, Deepti Bal, Selvakumar Selvaganesan, Santhi Thinahar, Kevin Robbie John, George Abraham Ninan, Shalini Nair, Swaminathan G, Krishna Prabhu, et al.

    Background: Malignant hemispheric infarction (MHI) is associated with high early mortality when managed conservatively. Decompressive hemicraniectomy (DHC) improves survival, but long-term functional outcomes and caregiver burden in low-resource settings remain poorly characterised, particularly in India. This study aimed to evaluate long-term outcomes and caregiver burden among MHI survivors undergoing DHC at a tertiary care centre in South India. Methods: We conducted an ambispective study of adult patients who underwent DHC for MHI between 2018 and 2023 and had at least 6 months of follow-up. Functional outcome was assessed using the modified Rankin Scale (mRS) and caregiver burden was evaluated using the Zarit Burden Interview. Subgroup analyses were performed based on infarct lateralisation and timing of surgery. Logistic regression was used to identify predictors of a favourable functional outcome. Results: 66 patients (mean age 44±12.8 years; 80% male) were included, with a median follow-up of 2 years (IQR: 1–4). Overall mortality was 24.2% (n=16). Among the 50 survivors, 26 (52.0%) achieved a good functional outcome (mRS ≤3) and 13 (26.0%) achieved an excellent outcome (mRS ≤2). Infarct lateralisation did not significantly influence mortality or functional recovery. Although early surgery and higher admission Glasgow Coma Scale scores were associated with better outcomes in univariate analysis, these factors were not significant in multivariate models. Caregivers of patients with mRS >2 reported significantly higher burden, particularly in emotional, physical and social domains. Conclusions: DHC for MHI results in meaningful long-term survival and functional recovery in selected patients, regardless of hemisphere involvement. However, residual disability imposes a substantial caregiver burden. Stroke care pathways in resource-limited settings should incorporate comprehensive rehabilitation and long-term caregiver support.

  • Open Access

    Stroke recovery patterns and predictors in India: A post-hoc analysis from the ATTEND trial

    by Sr Mishra, Jd Pandian, S Aaron, M Bk, Nc Borah, A Forster, Dbc Gandhi, Ds Halprashant, Ml Hackett, LA Harvey, et al.

  • Long-term outcomes and complications of cerebral venous sinus thrombosis: Findings from the Vellore CVT registry

    by Sanjith Aaron, Angel Miraclin T, Mubasheera Sulthana, Mahasampath Gowri, Premkumar Asokan, Deepti Bal, George Abraham Ninan, Selvakumar Selvaganesan, Anitha Jasper, Harshad Arvind Vanjare, et al.

    Background: Although short-term outcomes are generally favorable in Cerebral venous sinus thrombosis (CVT), there are limited data on long-term complications and sequelae. Methods: This ambispective study is from the Vellore CVT Registry, the largest single-center CVT registry in the world. Two thousand four hundred and eighty-four adults with CVT enrolled between 2000 and 2024 were analyzed for functional status and complications with follow-up up to 12 years. Results: Of 2484 patients, 2380 (95.8%) survived the acute phase, with a mean follow-up of 3.2 years (range, 0–12 years). During follow-up, 41 patients (1.7%) died, the majority being within 1 year. Excellent functional outcomes (mRS ⩽ 2) were achieved by 92% of patients within 2 years. Complications were observed in 799 (33.5%) at follow-up, of whom 405 (50.6%) required rehospitalization. More than half (55.1%) of these complications occurred more than 2 years after the initial diagnosis of CVT. Common complications were seizures (9.6%) and headaches (7.7%). Bleeding events occurred in 3.9% of cases, predominantly due to anticoagulant use. Recurrent CVT developed in 1.3%, and other thrombotic events in 2.4%. Occurrences of malignancies (1%) and secondary dural arteriovenous fistulas (dAVFs) (0.6%) were significant complications that occurred after 2 years. Of the 108 pregnancies that occurred during follow-up, thrombotic events occurred in 2.7% in the absence of antithrombotic prophylaxis. Conclusions: Most patients with CVT achieve long-term functional independence, yet one-third develop delayed complications. These findings underscore the importance of long-term surveillance in CVT survivors and give important insights into the natural history of CVT.


  • Open Access

    Quality of life after decompressive surgery for severe cerebral venous thrombosis

    by Mayte Sanchez van Kammen, Sanjit Aaron, Jorge M Ferreira, Patrícia Canhão, Adriana B. Conforto, Antonio Arauz, Marta Carvalho, Jaime Masjuan, Vijay K Sharma, Jukka Putaala, et al.

  • Open Access

    Seizures after decompressive surgery for cerebral venous thrombosis

    by Mayte Sanchez van Kammen, Sanjit Aaron, Jorge M. Ferreira, Patrícia Canhão, Adriana B. Conforto, Antonio Arauz, Marta Carvalho, Jaime Masjuan, Vijay K. Sharma, Jukka Putaala, et al.

    Introduction: The incidence and outcomes of seizures among patients with severe cerebral venous thrombosis treated with decompressive surgery are unknown as are potential predictors of seizures in these patients. Patients and methods: We report data from a multicenter, consecutive cohort including patients with cerebral venous thrombosis treated with decompressive surgery from 15 hospitals in 10 different countries between December 2011 and December 2019. We analyzed the cumulative incidence of seizures within one year after decompressive surgery and performed an exploratory analysis of potential factors associated with the incidence of post-surgery seizures, adjusted for competing mortality risk. Results: Of 116 included patients (median age 38 years [IQR 27–46], 68% female), 26 (22%) had seizures within one year after decompressive surgery. The mortality-adjusted cumulative one-year incidence of a first seizure after surgery was 23% (95% CI 16–31). Only aphasia at presentation predicted post-surgery seizures. Among patients who had a post-surgery seizure, the first seizure occurred despite active treatment with anti-seizure medications in 83% of patients. Recurrent seizures within the first year after surgery were reported in 63% of patients. Discussion and conclusion: Despite extensive use of anti-seizure medications, in patients with cerebral venous thrombosis treated with decompressive surgery the rate of seizures was 23% (95% CI 16–31) within one year after surgery. Of the patients who had a seizure after surgery, 63% had a recurrent seizure within the first year post-surgery.


  • Open Access

    Timing of starting anticoagulation following decompressive surgery for cerebral vein and sinus thrombosis: An observational study

    by Mariana C Taveira, Sanjith Aaron, Jorge M Ferreira, Jonathan M Coutinho, Patrícia Canhão, Adriana Conforto, Antonio Arauz, Marta Carvalho, Jaime Masjuan, Vijay K Sharma, et al.

    Background: Anticoagulation is the mainstay acute therapy for cerebral venous thrombosis (CVT). Decompressive surgery is required in a small minority of patients with large parenchymal lesions and impending herniation, which requires a temporary suspension of anticoagulation. Aim: The objective of this study was to identify the optimal timing for starting or resuming anticoagulation following decompressive surgery. Methods: Data were collected from the Decompressive Surgery for CVT Study 2 (DECOMPRESS2), a prospective multinational cohort observational study of 118 patients with severe CVT treated by decompressive surgery. We assessed the frequency of new hemorrhagic and venous thrombotic events from admission to discharge in patients who started or resumed anticoagulation 2) at discharge and at 1 year follow-up and compared between the two groups. Results: Of the 90 patients available for analysis, 35 (39%) started or resumed anticoagulation within the first 24 h after surgery while 55 (61%) did so later than 24 h. Overall frequency of patients with new hemorrhagic or venous thrombotic events from admission to discharge was 26.7% (24 patients), without crude or adjusted for the propensity score statistically significant difference between the early and late anticoagulation groups (2 = 0.33, p = 0.57). The distribution of major hemorrhagic events was also comparable: 8 (23%) bleedings in the 2 = 0.24, p = 0.62). No CVT recurred. Two venous thrombotic events occurred in <24 h (6%) and 5 in the ⩾24 h (9%) group. There was no association between anticoagulation timing and death or dependence (mRS 3-6) at discharge (OR: 1.65. 95% CI: 0.30 to 9.01, p = 0.56), or at 1 year follow-up (OR: 2.19, 95% CI: 0.78 to 6.10, p = 0.14). Conclusions: The results of this cohort study suggest that the timing of anticoagulation therapy following decompressive surgery for CVT does not significantly influence the risk of new bleeding or venous thrombotic events or disability.


  • Indian Trial of Tranexamic acid in Spontaneous Intracerebral Hemorrhage study protocol

    by Jeyaraj Durai Pandian, Atul Phillips, Shweta Jain Verma, Deepti Arora, Aneesh Dhasan, Pheba S Raju, Pn Sylaja, Biman Kanti Ray, Uddalak Chakraborty, Jacob Johnson, et al.

    Rationale: Early mortality in intracerebral hemorrhage (ICH) is due to hematoma volume (HV) expansion, and there are no effective treatments available other than reduction in blood pressure. Tranexamic acid (TXA) a hemostatic drug that is widely available and safe can be a cost-effective treatment for ICH, if proven efficacious. Hypothesis: Administration of TXA in ICH patients when given within 4.5 h of symptom onset will reduce early mortality at 30 days. Design: Indian Trial of Tranexamic acid in Spontaneous Intracerebral Haemorrhage (INTRINSIC trial) is a multicenter, randomized, open-label, trial enrolling patients aged more than 18 years presenting with non-traumatic ICH within 4.5 h of symptom onset or when last seen well. Study participants received 2 g of TXA administered within 45 min while control group received standard of care. Intensive blood pressure reduction as per INTERACT 2 protocol is followed is done in both groups. Study plans to recruit 3400 patients. Primary outcome is mortality at day 30. Secondary outcomes are radiological reduction in HV at 24 h from baseline, neurological impairment at day 7 or earlier (if discharged), and assessments of dependency and quality of life at day 90. Summary: If proven to be beneficial, TXA will have a major impact on medical management of ICH. Trial registration: Clinical Trial Registry India (CTRI/2023/03/050224) and Clinical Trials.gov (NCT05836831).


  • Open Access

    Cerebral Venous Sinus Thrombosis: Current Updates in the Asian Context

    by Angel Miraclin T, Deepti Bal, Ivy Sebastian, Satish Shanmugasundaram, Sanjith Aaron, Jeyaraj D. Pandian

    Background: Cerebral venous sinus thrombosis (CVT) is a life-threatening cause of stroke in Asian countries. South Asia, comprising of India, Pakistan, and Bangladesh, contributed to 40% of strokes in women. Major CVT registries are from the Western nations, which differs from the Asian countries with respect to epidemiology, gender biases, and risk factors. This review focuses on the various aspects of relevance in evaluation and management of patients with CVT in the Asian context. Summary: The incidence of CVT is higher in Asia than in Western nations. Young age, female gender, especially in pregnancy and puerperal period, and dehydration appear to be the critical risk factors. Tropical infections like malaria, scrub typhus, and flaviviral encephalitis predispose to CVT. There is a higher prevalence of inherited thrombophilia in the Asian cohorts, contributing to prothrombotic states. Anticoagulation and supportive management offer excellent outcomes. Newer anticoagulants are safe and efficacious. In medically refractory cases, endovascular treatment offers modest benefits. Decompressive hemicraniectomy, when done early, offers mortality benefits in patients with large hemorrhagic venous infarctions. Key Messages: CVT is an important cause of stroke with a high burden in South Asian countries. Establishment of robust registries is the need of the hour to study the natural history, course, and outcomes and to develop management algorithms tailored to the available resources.


  • Outcomes of Decompressive Surgery for Patients With Severe Cerebral Venous Thrombosis: DECOMPRESS2 Observational Study

    by Sanjit Aaron, Jorge M. Ferreira, Jonathan M. Coutinho, Patrícia Canhão, Adriana B. Conforto, Antonio Arauz, Marta Carvalho, Jaime Masjuan, Vijay K. Sharma, Jukka Putaala, et al.

    BACKGROUND: Decompressive neurosurgery is recommended for patients with cerebral venous thrombosis (CVT) who have large parenchymal lesions and impending brain herniation. This recommendation is based on limited evidence. We report long-term outcomes of patients with CVT treated by decompressive neurosurgery in an international cohort. METHODS: DECOMPRESS2 (Decompressive Surgery for Patients With Cerebral Venous Thrombosis, Part 2) was a prospective, international cohort study. Consecutive patients with CVT treated by decompressive neurosurgery were evaluated at admission, discharge, 6 months, and 12 months. The primary outcome was death or severe disability (modified Rankin Scale scores, 5–6) at 12 months. The secondary outcomes included patient and caregiver opinions on the benefits of surgery. The association between baseline variables before surgery and the primary outcome was assessed by multivariable logistic regression. RESULTS: A total of 118 patients (80 women; median age, 38 years) were included from 15 centers in 10 countries from December 2011 to December 2019. Surgery (115 craniectomies and 37 hematoma evacuations) was performed within a median of 1 day after diagnosis. At last assessment before surgery, 68 (57.6%) patients were comatose, fixed dilated pupils were found unilaterally in 27 (22.9%) and bilaterally in 9 (7.6%). Twelve-month follow-up data were available for 113 (95.8%) patients. Forty-six (39%) patients were dead or severely disabled (modified Rankin Scale scores, 5–6), of whom 40 (33.9%) patients had died. Forty-two (35.6%) patients were independent (modified Rankin Scale scores, 0–2). Coma (odds ratio, 2.39 [95% CI, 1.03–5.56]) and fixed dilated pupil (odds ratio, 2.22 [95% CI, 0.90–4.92]) were predictors of death or severe disability. Of the survivors, 56 (78.9%) patients and 61 (87.1%) caregivers expressed a positive opinion on surgery. CONCLUSIONS: Two-thirds of patients with severe CVT were alive and more than one-third were independent 1 year after decompressive surgery. Among survivors, surgery was judged as worthwhile by 4 out of 5 patients and caregivers. These results support the recommendation to perform decompressive neurosurgery in patients with CVT with impending brain herniation.